Survodutide: SYNCHRONIZE-1 Phase 3 Results & GLP-1/Glucagon Profile

What Is Survodutide?

Survodutide (development code BI 456906) is a once-weekly injectable peptide that simultaneously activates the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is a unimolecular dual agonist — a single engineered peptide, not a co-formulation of two drugs — which places it mechanistically between pure GLP-1 agonists like semaglutide and triple agonists like the retatrutide profile compound.

The compound was originated by Zealand Pharma and licensed to Boehringer Ingelheim for global clinical development. Boehringer leads the Phase 3 programme across obesity, MASH (metabolic dysfunction-associated steatohepatitis), and cardiovascular outcomes. Zealand retains milestone and royalty rights and publishes programme-level disclosures. For broader context on where survodutide sits among next-generation obesity compounds, see our obesity drug approval tracker 2026.

Mechanism of Action

Survodutide engages two receptors that contribute to weight loss through complementary pathways:

• GLP-1 receptor: Central appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion. Same pathway used by semaglutide and tirzepatide.
• Glucagon receptor: Increases hepatic lipid oxidation, stimulates resting energy expenditure, and contributes to reductions in liver fat content. This arm is the mechanistic rationale for survodutide’s MASH programme.

Survodutide differs from pure GLP-1 agonists (semaglutide, liraglutide) by adding the energy-expenditure arm. It differs from GLP-1/GIP agonists (tirzepatide) by using glucagon instead of GIP as the second receptor. It differs from GLP-1/amylin combinations (CagriSema) in both receptor target and formulation strategy — CagriSema is two molecules, survodutide is one.

Development Stage & Trial Pipeline

Survodutide is in Phase 3 across three programme pillars. SYNCHRONIZE-1 reported topline in May 2026 (16.6% at 76 weeks). As of June 2026, no NDA has been filed.

Current status: Phase 3 (SYNCHRONIZE programme); SYNCHRONIZE-1 reported May 2026; MASH (LIVERAGE / LIVERAGE-Cirrhosis) programme continues to recruit; no NDA / MAA filed. Boehringer Ingelheim has not publicly committed to a filing date. MASH would likely follow a separate submission pathway on the LIVERAGE / LIVERAGE-Cirrhosis data. For live tracking, see Is survodutide approved?.

Efficacy Data — Phase 3 SYNCHRONIZE-1

SYNCHRONIZE-1 reported in May 2026 as the first Phase 3 obesity readout for survodutide. In adults with obesity or overweight, survodutide produced 16.6% mean weight loss at 76 weeks, with absolute loss up to 17.8 kg (~39.2 lbs), versus 3.2% on placebo. The figure is a mean across all doses studied; dose-by-dose Phase 3 splits were not in the topline disclosure and will follow with full data publication. Analyst commentary at the time of readout noted survodutide fell short of tirzepatide and retatrutide on pure weight loss but kept the glucagon arm open as a differentiator on cardiometabolic and liver outcomes.

Phase 2 Reference

The pivotal Phase 2 survodutide obesity trial was a randomised, double-blind, placebo-controlled dose-ranging study evaluating 0.6, 2.4, 3.6, and 4.8 mg once-weekly doses over 46 weeks in adults with overweight or obesity. Results were published in The Lancet in 2024.

The dose-response relationship was clear: each step in dose produced additional weight loss, with the top 4.8 mg arm delivering the headline 18.7% reduction at 46 weeks. Waist circumference, HbA1c, blood pressure, and lipid parameters all improved in a dose-dependent pattern. Phase 2 MASH data have also been published and show liver-fat reductions consistent with the glucagon-receptor rationale.

With the SYNCHRONIZE-1 Phase 3 readout now in hand at 16.6% mean weight loss at 76 weeks (up to 17.8 kg absolute), the headline obesity figure is Phase 3, not Phase 2. The 18.7% Phase 2 number remains useful as a dose-by-dose reference until Boehringer Ingelheim and Zealand Pharma publish per-dose Phase 3 splits.

Safety & Tolerability

Phase 2 survodutide showed the gastrointestinal (GI) adverse-event profile expected for the GLP-1 class, with a glucagon overlay that increases metabolic signals such as transient heart-rate elevation. Adverse events were dose-dependent and concentrated in the escalation period. The SYNCHRONIZE-1 topline disclosure did not include dose-by-dose Phase 3 safety splits; full safety data will publish with the broader Phase 3 readout.

• Most common AEs (Phase 2): nausea, vomiting, diarrhea, decreased appetite, constipation. Consistent with GLP-1 class effects.
• GI AE incidence by dose (Phase 2, approximate): low doses reported nausea in the ~30–40% range; the 4.8 mg arm trended higher, broadly in line with top-dose tirzepatide and semaglutide cohorts.
• Discontinuation: Treatment discontinuation due to AEs was low at lower doses and rose with dose escalation at 4.8 mg, again mirroring class patterns. Exact per-dose discontinuation percentages should be read from the published Lancet paper.
• Metabolic signals: Small increases in heart rate were observed, consistent with glucagon-receptor activation. No unexpected safety signals were disclosed in Phase 2.

Long-term tolerability, rare AEs, and cardiovascular safety will be characterised by the full Phase 3 SYNCHRONIZE programme and SYNCHRONIZE CVOT, beyond the SYNCHRONIZE-1 topline.

How It Compares — Survodutide vs Retatrutide

The retatrutide profile compound (Eli Lilly) is a triple agonist targeting GLP-1, GIP, and glucagon. Survodutide is a dual agonist targeting GLP-1 and glucagon only. Both engage the glucagon arm — so both mobilise hepatic lipid oxidation and energy expenditure — but retatrutide adds GIP as a third pathway.

On Phase 3 data, retatrutide’s TRIUMPH-1 reported 28.3% weight loss at 80 weeks at the top dose, while survodutide’s SYNCHRONIZE-1 (May 2026) reported 16.6% mean weight loss at 76 weeks with absolute loss up to 17.8 kg. Direct cross-trial comparisons are limited by different populations, titration schedules, and endpoints, but retatrutide leads survodutide on absolute weight loss. Survodutide’s counter is the glucagon arm’s potential liver and cardiometabolic angle, anchored by the FDA Breakthrough Therapy-designated LIVERAGE / LIVERAGE-Cirrhosis Phase 3 MASH programme that retatrutide does not currently match. For a deeper mechanism-level read, see our survodutide vs retatrutide comparison.

Research Use Notes

Survodutide is not currently available through Remy Peptides. The compound remains proprietary to Boehringer Ingelheim and Zealand Pharma and is not distributed as a reference standard through mainstream research-supply channels. Researchers interested in dual-agonist pharmacology typically work with published Phase 2 literature and class-adjacent reference peptides until survodutide enters broader research use.

Remy Peptides supplies HPLC-verified retatrutide pens (Janoshik Analytical Batch RETP002, 99.262% purity) as its anchor triple-agonist reference compound for in-vitro laboratory research. Retatrutide shares the glucagon-receptor arm with survodutide and adds GIP, making it a useful reference for laboratories characterizing glucagon-pathway effects. For full laboratory context on retatrutide, see our retatrutide in Dubai research guide.

All Remy Peptides products are supplied for in-vitro laboratory research only. Not for human or veterinary use. UAE MoHAP Circular 17/2022 compliance statement.